Logo
Nazad
S. Bešlija, M. Banjin, S. Jungić, Nermina Obralic, G. Kecman-Malcic, I. Rakita, B. Salkić, A. Pašić, L. Tinjić, E. Ajanović
0 20. 6. 2007.

Preliminary phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)

14502 Background: The oral fluoropyrimidine X (Xeloda®) has improved efficacy, safety and convenience compared with 5-FU/LV in MCRC [Van Cutsem et al. Br J Cancer 2004] and early-stage colon cancer...


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više